Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Evaluation of men on finasteride

G J Gormley1

  • 1Merck Research Laboratories, Rahway, NJ 07065, USA.

Seminars in Urologic Oncology
|August 1, 1996
PubMed
Summary

Finasteride, a 5 alpha-reductase inhibitor, effectively shrinks the prostate and lowers testosterone conversion to dihydrotestosterone. It does not impede prostate cancer detection when its PSA effects are considered.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The importance of human factors in right-left errors.

Anaesthesia·2018
Same author

Living with 'melanoma' … for a day: a phenomenological analysis of medical students' simulated experiences.

The British journal of dermatology·2017
Same author

Implications of aligning full registration of doctors with medical school graduation: a qualitative study of stakeholder perspectives.

BMJ open·2016
Same author

Non-steroidal anti-inflammatory drug use and cervical cancer risk: a case-control study using the Clinical Practice Research Datalink.

Cancer epidemiology·2013
Same author

Dyspepsia.

BMJ (Clinical research ed.)·2011
Same author

The use of real patients in OSCEs: a survey of medical students’ predictions and opinions.

Medical teacher·2011

Area of Science:

  • Pharmacology
  • Urology
  • Endocrinology

Background:

  • Finasteride inhibits type II 5 alpha-reductase, blocking testosterone to dihydrotestosterone conversion.
  • Benign prostatic hyperplasia (BPH) management is a documented utility of finasteride.
  • The drug reduces prostate volume and serum levels.

Purpose of the Study:

  • To summarize the effects and monitoring guidelines for finasteride in BPH management.
  • To address concerns regarding finasteride's impact on prostate cancer detection.

Main Methods:

  • Review of finasteride's mechanism of action.
  • Analysis of clinical outcomes in patients using finasteride for BPH.
  • Evaluation of prostate cancer screening parameters during finasteride treatment.

Main Results:

  • Finasteride effectively reduces prostate size and associated serum markers.
  • Monitoring requires digital-rectal examination (DRE) and prostate-specific antigen (PSA) measurement.
  • Abnormal findings necessitate further investigation.

Conclusions:

  • Finasteride is effective for BPH, reducing prostate volume and PSA levels.
  • Awareness of finasteride's effect on PSA is crucial for accurate prostate cancer screening.
  • No adverse impact on prostate cancer detection if PSA alterations are accounted for.

Related Experiment Videos